Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Karl Anders Harfstrand was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 07
KDventures AB, Annual General Meeting, May 12, 2026 KDventures AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: nanna svartz vag 2, 171 65 solna, solna Sweden Announcement • Mar 03
KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome KDventures AB announced that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered into between the parties in connection with the acquisition. In 2021, Organon acquired KDventures' portfolio company Forendo, but in July 2025 discontinued development of OG-6219, its most advanced drug candidate targeting endometriosis. The acquisition also included a preclinical drug candidate for polycystic ovary syndrome. Organon has now announced that development of this drug candidate has also been discontinued. This announcement means that the value of KDventures' share of the parties’ agreement on potential additional purchase considerations will be written off in its entirety, which will be reported in the interim report for the first quarter of 2026. Announcement • Jan 29
Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million. Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million.
Security Name: Class B Shares
Security Type: Common Stock
Securities Offered: 384,166,664
Price\Range: SEK 0.3
Transaction Features: Rights Offering Announcement • Dec 01
Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million. Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million.
Security Name: Class B Shares
Security Type: Common Stock
Securities Offered: 675,193,985
Price\Range: SEK 0.3
Transaction Features: Rights Offering Announcement • Nov 05
Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemia Karolinska Development AB announced that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in fourth quarter of 2025, in line with the company's development timeline. Modus Therapeutics, listed on Nasdaq First North Growth Market, has received approval from regulatory authorities in Italy to initiate the second part of The company's phase 2 study with sevuparin in patients with chronic kidney disease with anemic. Three doses of sevuparin will be evaluated in the second part of the clinical study, based on single-dose data from the initial part, where data shows that sevuparin was well-tolerated. Announcement • Sep 04
Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million. Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million.
Security Name: Shares
Security Type: Common Stock
Transaction Features: Rights Offering Announcement • Jun 30
An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV). An undisclosed buyer acquired an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025.
An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025. Announcement • Apr 08
Karolinska Development AB (publ), Annual General Meeting, May 15, 2025 Karolinska Development AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at nanna svartz vag 2, 17165 solna, Sweden Announcement • Dec 19
Karolinska Development AB Announces Changes to Chairman Karolinska Development AB announced that its Board of Directors has appointed Ben Toogood as new Chairman until the next General Meeting. Karolinska Development’s Board of Directors has internally appointed its member Ben Toogood as new Chairman, following Professor Hans Wigzell’s resignation from the position at his own request. Ben Toogood has been a member of the Board since 2021 and is beyond the assignment also Head of Global Business Development at Sino Pharmaceuticals Limited, CEO at invoX Pharma Limited and Director at Softhale BV and pHion Therapeutics. Announcement • Dec 11
Karolinska Development AB (Publ) Announces Resignation of Hans Wigzell as Chairman of the Board Karolinska Development AB announced that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors will immediately initiate a process to appoint a new Chairman. Hans Wigzell has been an instrumental force in Karolinska Development ever since the company was founded. He has served as Chairman of the Board during several periods, most recently since the 2024 Annual General Meeting. Reported Earnings • Nov 17
Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023) Third quarter 2024 results: kr0.04 loss per share (down from kr0.044 profit in 3Q 2023). Net loss: kr10.9m (down 191% from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance. Announcement • Nov 15
Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines Karolinska Development AB announced that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from November 15, 2024, as Dr Richard Bethell has decided to step down as CEO to pursue other professional interests while remaining associated with the company in an advisory role. Dr. Gaston Picchio has over 30 years of experience in clinical virology from his previous roles at the Scripps Research Institute, Johnson & Johnson, and Arbutus Biopharma. While at Johnson & Johnson, Dr. Picchio was involved in the development and approval of antivirals and vaccines for HIV, HCV, and Zika. Most recently, he comes from Arbutus Biopharma, where he led the development of novel therapeutic combinations aimed at curing chronic hepatitis B. Announcement • Sep 23
An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV). An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024.
An undisclosed buyer completed the acquisition of 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024. Reported Earnings • Sep 01
Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023) Second quarter 2024 results: kr0.059 loss per share (down from kr0.086 profit in 2Q 2023). Net loss: kr16.0m (down 169% from profit in 2Q 2023). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance. New Risk • May 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings are forecast to decline by an average of 72% per year for the foreseeable future. Revenue is less than US$1m (kr1.9m revenue, or US$184k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€36.7m market cap, or US$39.9m). Reported Earnings • Apr 28
First quarter 2024 earnings released First quarter 2024 results: Net income: kr208.0k (up kr28.2m from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Apr 16
Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election Karolinska Development AB (publ) announced that Björn Cochlovius has declined re-election. Reported Earnings • Mar 25
Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022) Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 5% per year. New Risk • Mar 24
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 45% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$191k). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€37.5m market cap, or US$40.5m). Recent Insider Transactions • Feb 28
Chief Executive Officer recently bought €7.2k worth of stock On the 19th of February, Viktor Drvota bought around 50k shares on-market at roughly €0.14 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Viktor's only on-market trade for the last 12 months. Reported Earnings • Feb 18
Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022) Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year. New Risk • Nov 19
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 67% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 67% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$194k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€38.3m market cap, or US$41.8m). Announcement • Nov 09
Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million. Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,150,000
Price\Range: SEK 2
Transaction Features: Rights Offering Announcement • Sep 21
Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery Karolinska Development AB announced that its portfolio company OssDsign has received clearance from FDA for the use of OssDsign Catalyst in interbody cages in spinal surgery. The FDA clearance creates possibilities in a new indication with major market potential for the company's innovative nanosynthetic bone graft. The clearance from the U.S. Food and Drug Administration (FDA) allows surgeons to use the OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone. The decision by the FDA is based on OssDsign's outstanding bone regeneration results which surpass other synthetic bone grafts in challenging evaluation models. Reported Earnings • Aug 27
Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022) Second quarter 2023 results: EPS: kr0.086 (up from kr0.083 loss in 2Q 2022). Net income: kr23.3m (up kr45.6m from 2Q 2022). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.1%. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 28
Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021) Full year 2022 results: kr0.34 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 4.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 18
Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021) Full year 2022 results: kr3.43 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 7.1% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.5%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Announcement • Feb 15
Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data Karolinska Development AB (publ) announced that its portfolio company Dilafor’s extended clinical phase 2b study with the drug candidate tafoxiparin has resulted in further positive data. The extension of the study met its objective, which was to evaluate if the efficacy of tafoxiparin obtained in the phase 2b trial persists when the drug is administered in additional doses. In a clinical phase 2b study, tafoxiparin showed a significant positive effect on cervical ripening in first-time mothers that were given treatment for a planned start of labor. The completed extension of the phase 2b study included a total of 164 women, and the results show that the cervical ripening effect persists in the study. In addition, a clear dose-response relationship was observed. Up to 30% of all pregnant women are subject to planned start of labor, the current interventions increase the risk of medical complications in both mother and child, leading to high healthcare costs. Karolinska Development's direct ownership in Dilafor amounts to 1% and indirect ownership interest via KDev Investment in Dilafor amounts to 30%. Reported Earnings • Nov 19
Third quarter 2022 earnings released Third quarter 2022 results: Net loss: kr46.6m (loss widened kr45.4m from 3Q 2021). Revenue is expected to decline by 3.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.9%. Announcement • Nov 18
Karolinska Development AB (publ), Annual General Meeting, May 16, 2023 Karolinska Development AB (publ), Annual General Meeting, May 16, 2023. Board Change • Nov 16
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • Aug 20
Second quarter 2022 earnings released Second quarter 2022 results: Net loss: kr22.3m (down 110% from profit in 2Q 2021). Over the next year, revenue is expected to shrink by 8.1% compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Reported Earnings • May 01
First quarter 2022 earnings released First quarter 2022 results: Net loss: kr29.2m (loss widened 17% from 1Q 2021). Over the next year, revenue is expected to shrink by 6.1% compared to a 8.1% growth forecast for the industry in Germany. Board Change • Apr 27
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Announcement • Apr 26
Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study Karolinska Development AB (publ) announced that its portfolio company OssDsign has enrolled all patients in the clinical study TOP FUSION, which will primarily evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. OssDsign will now follow the patients recruited for the study for 24 months. The outcome of the study will primarily focus on healing between the vertebrae and the lack of treatment-related side effects. The company’s nanosynthetic bone graft OssDsign Catalyst received FDA approval in 2020 and was launched on the US market in August 2021. Karolinska Development's shareholding in OssDsign AB, including indirect ownership via KCIF Co-Investment Fund, amounts to 10.4%. Reported Earnings • Feb 28
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: kr0.97 (up from kr1.18 loss in FY 2020). Net income: kr170.8m (up kr378.3m from FY 2020). Revenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 7.8% compared to a 7.8% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Announcement • Feb 08
Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million. Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.
Security Name: Class B Shares
Security Type: Common Stock
Securities Offered: 93,360,022
Price\Range: SEK 4
Security Name: Class A Shares
Security Type: Common Stock
Securities Offered: 1,052,163
Price\Range: SEK 4
Transaction Features: Rights Offering Announcement • Dec 14
Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others. Organon & Co. (NYSE:OGN) agreed to acquire Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others for approximately $950 million on November 11, 2021. Under the agreement, Organon & Co. shall make an initial payment of $75 million. In addition, there are conditional payments totaling $270 million linked to milestones in the development and registration processes for the company's drug candidates, and additional payments totaling $600 million linked to commercial milestones. The completion of the transaction is subject to review by competition authorities and other customary conditions. The transaction is expected to close in December 2021.
Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others on December 11, 2021. The consideration for the transaction includes a $75 million upfront payment, assumption of approximately $9 million of Forendo debt, payments upon the achievement of certain development and regulatory milestones of up to $270 million and commercial milestones payments of up to $600 million, which together could amount to total consideration of $954 million. Moelis & Company acted as exclusive financial advisor to Forendo. Announcement • Dec 02
Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin Karolinska Development AB (publ) announced that its portfolio company Modus Therapeutics has dosed the first subject in a phase 1b study of sevuparin. The drug candidate is being developed as a potential treatment for sepsis/septic shock, a serious and often fatal condition. The randomized, placebo-controlled Phase 1b study will evaluate the effect of sevuparin on symptoms in healthy individuals injected with the bacterial toxin lipopolysaccharide (LPS) in the skin (local inflammation) and in the blood (systemic inflammation). Provocation with LPS is a well-established experimental model to characterize the early stages of septic inflammation by eliciting measurable symptoms. In addition, the study will evaluate the safety profile of sevuparin when used in combination with standard prophylactic blood-thinning heparin therapy. Reported Earnings • Nov 19
Third quarter 2021 earnings released Third quarter 2021 results: Net loss: kr1.20m (loss narrowed 99% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Nov 16
Investor sentiment improved over the past week After last week's 174% share price gain to €1.13, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 79% over the past three years. Reported Earnings • Aug 21
Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020) Second quarter 2021 results: Net income: kr216.4m (up kr214.3m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Announcement • Aug 13
Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program Karolinska Development AB announced that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics clinical program evaluating eprenetapopt with acalabrutinib or venetoclax and rituximab in lymphoid malignancies. The issue means there will be a pause in the patient enrollment until the agency reverses the decision. Patients previously enrolled and showing positive clinical responses will continue to receive study treatment. Aprea Therapeutics was initially notified of a partial hold in the myeloid malignancy clinical program and shortly thereafter received notification from the FDA that a clinical hold had also been issued in the ongoing lymphoid malignancy study. The agency's decision is related to the safety and efficacy data presented in a recent Phase 3 study of eprenetapopt in TP53-mutaed myelodysplastic syndrome (MDS). Aprea Therapeutics intends to work in close dialogue with the FDA to clarify and address the agency's concerns in order to resume activity in the clinical trial program as soon as possible. Karolinska Development has an interest in Aprea Therapeutics through KDev Investment amounting to a total holding of 8.4% of the outstanding shares in Aprea Therapeutics. Announcement • Jun 18
Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB. Karolinska Development AB (publ) (OM:KDEV) acquired 21% stake in Anacardio AB on June 17, 2021. The consideration received under the transaction is intended to cover costs for necessary activities prior to a planned major capital raising to finance the first part of the project's clinical development.
Karolinska Development AB (publ) (OM:KDEV) completed the acquisition of 21% stake in Anacardio AB on June 17, 2021. Reported Earnings • May 01
First quarter 2021 earnings released First quarter 2021 results: Net loss: kr24.9m (loss narrowed 80% from 1Q 2020). Reported Earnings • Mar 31
Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019) Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019). Executive Departure • Mar 10
CFO & Deputy CEO Fredrik Jarrsten has left the company On the 7th of March, Fredrik Jarrsten, was replaced as CEO by Viktor Drvota. As of December 2020, Fredrik personally held only 120.00k shares (€19k worth at the time). A total of 5 executives have left over the last 12 months. Announcement • Feb 27
Karolinska Development Appoints Johan Dighed as Deputy CEO Karolinska Development AB announced that Johan Dighed has been appointed as Deputy CEO. He takes up the position immediately and will, in addition to his new duties, continue to hold his current role as the company's General Counsel. Announcement • Feb 20
Karolinska Development AB (publ) Announces Management Appointments Karolinska Development AB (publ) held an Extraordinary General Meeting on February 19, 2021. At the Extraordinary General Meeting, it was resolved, in accordance with the Nomination Committee’s proposal, to elect Anna Lefevre Skjöldebrand and Ben Toogood as new directors, and to elect Björn Cochlovius as new chairman of the Board of Directors. Reported Earnings • Feb 12
Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019) Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019). Is New 90 Day High Low • Nov 19
New 90-day low: €0.21 The company is down 24% from its price of €0.27 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Is New 90 Day High Low • Oct 29
New 90-day low: €0.23 The company is down 13% from its price of €0.26 on 31 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Announcement • Jul 31
Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB. Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB on March 27, 2020. Karolinska Development AB (publ) has an option agreement to increase the ownership in Svenska Vaccinfabriken Produktion AB to a total of 25% within a defined period of time and at a predetermined price. Karolinska Development will be represented on the Svenska Vaccinfabriken Produktion AB Board of Directors.
Karolinska Development AB (publ) (OM:KDEV) completed the acquisition of 5% stake in Svenska Vaccinfabriken Produktion AB on March 27, 2020.